SCHEMBL7069989

SCHEMBL7069989

[CH]1NCCC1c1cccs1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
MAPT P10636 6/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
KDM4E B2RXH2 5/20 0.36
HPGD P15428 3/20 0.36
ALOX15 P16050 2/20 0.36
ALOX12 P18054 1/20 0.36
GAA P10253 2/20 0.35
NPC1 O15118 1/20 0.35
TP53 P04637 1/20 0.35
MAPK1 P28482 1/20 0.35
RAB9A P51151 1/20 0.35
HSD17B10 Q99714 1/20 0.35
TSHR P16473 1/20 0.35
HTT P42858 1/20 0.35
POLB P06746 1/20 0.34
BRD4 O60885 2/20 0.33
NOS2 P35228 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7416329 0.81 ALDH1A1 (0.36) ALDH1A1MEN1KMT2AMAPTSMN1; SMN2
SCHEMBL5467244 0.71 SLC18A3 (0.48) ALDH1A1MEN1KMT2AMAPTSMN1; SMN2
SCHEMBL497608 0.71
Hydrochloric Acid SCHEMBL2803164 0.69 SLC18A3 (0.47) ALDH1A1MEN1KMT2AMAPTGAA
Hydrochloric Acid SCHEMBL11286601 0.69
SCHEMBL3657117 0.69
SCHEMBL9693463 0.68 KDM4E (0.47) ALDH1A1MEN1KMT2AMAPTSMN1; SMN2
SCHEMBL6179170 0.68 CHRM5 (0.46) ALDH1A1MEN1KMT2ASMN1; SMN2POLB
SCHEMBL3648603 0.68 HTR3A (0.44) ALDH1A1MEN1KMT2AMAPTGAA
SCHEMBL166764 0.68 CHRM5 (0.46) ALDH1A1MEN1KMT2ASMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6586602-B2 CD antigen antagonists such as N-(methanesulfonyl)-L-prolyl-L-phenylalanine and prodrugs used as antiinflammatory agents BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) 2003-07-01 US claimed
US-20030065193-A1 Benzyl compounds which inhibit leukocyte adhesion mediated by VLA-4 BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) 2003-04-03 US claimed
US-6362341-B1 ANTIINFLAMMATORY AGENTS ATHENA NEUROSCIENCES, INC. 2002-03-26 US claimed
EP-1001975-A1 BENZYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 Elan Pharmaceuticals, Inc. (US) 2000-05-24 EP claimed
WO-1999006436-A1 BENZYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 ELAN PHARMACEUTICALS, INC. (US) 1999-02-11 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030065193-A1 Benzyl compounds which inhibit leukocyte adhesion mediated by VLA-4 VCAM1, ICAM1, ITGB4 ALDH1A1 369/4885MEN1 1824/4885KMT2A 1002/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.